The Mesoblast (ASX:MSB) share price has tumbled 25% in a month. What's going on?

It's been a tough month on the ASX for Mesoblast.

| More on:
A man wearing a white coat and glasses is wide-mouthed in surprise.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Limited (ASX: MSB) share price has had a hard time of it lately. Its struggles seem to have been born from a 17% single-day plunge last month, from which the company – whose stock is also listed on the Nasdaq exchange under the ticker NASDAQ: MESO – hasn't yet managed to recover.

In early morning trade on Wednesday, the Mesoblast share price is $1.36. That's 20% lower than it was this time last month.

Let's take a look at what's been weighing on the biotechnology company recently.

What's dragging the Mesoblast share price lower?

The Mesoblast share price has been feeling down since it announced a Swiss healthcare company dumped its product in mid-December.

Novartis terminated an agreement that could have seen Mesoblast's remestemcel-L used to treat COVID-19-induced acute respiratory distress syndrome (ARDS).

As The Motley Fool noted at the time, the agreement's cancellation saw around US$1.2 billion of Mesoblast's potential earnings washed down the drain.

Of course, the agreement's termination might have been expected by some.

It was put in place less than a month before Mesoblast released news its randomised control trial treating ventilator-dependent patients with ARDS due to COVID-19 was called off early after it became apparent it was unlikely to meet its primary endpoint.

The Mesoblast share price recovered some of its losses on 16 December. That's when the company released positive news of a trial using remestemcel-L to treat chronic back pain.

Its shares gained 11% that day, but they didn't manage to hold onto the boost.

In fact, the Mesoblast share price has already shed 3.55% year to date. It's also 47% lower than it was this time last year.

On top that that, Mesoblast remains one of the most shorted stocks on the ASX. The Motley Fool's most recent weekly breakdown of shorting found 9.1% of the company's shares were in the hands of short sellers.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »

three excited doctors with hands in the air
Healthcare Shares

Two ASX healthcare shares that could be set to double

This broker has buy recommendations on these two shares. 

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Telix shares jump 7% on big US news

Let's see what is getting investors excited on Wednesday.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Macquarie tips 28% upside for this ASX healthcare stock

The broker expects big things from this New Zealand retirement village developer and operator.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

$10,000 invested in these ASX healthcare shares 5 years ago is now worth…

These healthcare stocks have brought big returns for investors 

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Guess which ASX 300 stock is crashing 55% today

What's going on with this stock? Let's see why investors are hitting the sell button.

Read more »

Woman serving customer in pharmacy.
Healthcare Shares

Up 132% in a year, are Sigma Healthcare shares still a good buy post the Chemist Warehouse merger?

After gaining 132% in 12 months, it too late to buy Sigma Healthcare shares today?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Share Market News

Is it too late to buy Pro Medicus shares?

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in.

Read more »